11/01/2019 14:21:00

Monthly Factsheet and Commentary - December 2018

TwentyFour Select Monthly Income Fund - Monthly Factsheet and Commentary - December 2018

PR Newswire

31/12/2018

TWENTYFOUR SELECT MONTHLY INCOME FUND LIMITED

(a closed-ended investment company incorporated in Guernsey with registration number 57985, LEI: 549300P9Q5O2B3RDNF78)

Monthly Factsheet

Factsheet Commentary

TwentyFour Select Monthly Income Fund Limited has today published its monthly factsheet and commentary to the end of December 2018. Copies can be downloaded from the Company's website: 

https://www.selectmonthlyincomefund.com

For further information, please contact:

Numis Securities Limited:
Nathan Brown+44 (0)20 7260 1000
Hugh Jonathan
TwentyFour Select Monthly Income Fund Limited:
John Magrath+44 (0)20 7015 8900
Alistair Wilson

Related content
13 Jun - 
Net Asset Value(s)
13 Jun - 
Dividend
06 Jun - 
Net Asset Value(s)
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

13 Jun E:SMIF
13 Jun E:SMIF
06 Jun E:SMIF
04 Jun E:SMIF
03 Jun E:SMIF
30 May E:SMIF
23 May E:SMIF

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Related stock quotes


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:48:24
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-16 11:48:24 - 2019-06-16 10:48:24 - 1000 - Website: OKAY